Type I diabetes (T1D) is an autoimmune disease in which an immune response to pancreatic b-cells results in their loss over time. Although the conventional view is that this loss is due to autoimmune destruction, we present evidence of an additional phenomenon in which autoimmunity promotes islet endocrine cell transdifferentiation. The end result is a large excess of d-cells, resulting from a-to b-to d-cell transdifferentiation. Intermediates in the process of transdifferentiation were present in murine and human T1D. Here, we report that the peptide caerulein was sufficient in the context of severe b-cell deficiency to induce efficient induction of a-to b-to d-cell transdifferentiation in a manner very similar to what occurred in T1D. This was demonstrated by genetic lineage tracing and time course analysis. Islet transdifferentiation proceeded in an islet autonomous manner, indicating the existence of a sensing mechanism that controls the transdifferentiation process within each islet. The finding of evidence for islet cell transdifferentiation in rodent and human T1D and its induction by a single peptide in a model of T1D has important implications for the development of b-cell regeneration therapies for diabetes. Cell Death and Disease (2014) 5, e1357; doi:10.1038/cddis.2014.311; published online 31 July 2014
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The response of a tissue to stress/injury can involve cell death and proliferation. However, it has become increasingly recognized that changes in cellular differentiation state can have an important role. 1 In type I diabetes (T1D), the established view has been that the primary pathophysiological event is b-cell apoptosis due to a b-cell specific autoimmune response, 2 leading to profound b-cell deficiency. Thus, there has been great interest in inducing b-cell neogenesis, but there has been controversy over how and even whether b-cell regeneration occurs. 3 Activation of dedicated stem/progenitor cells within the pancreas and transdifferentiation of other differentiated cell types to b-cells are two potential mechanisms. In the past, the prevailing paradigm has been that neogenesis proceeds by the activation of facultative b-cell stem/progenitors within pancreatic ducts. [4] [5] [6] [7] However, more recent studies have not found evidence of robust b-cell neogenesis from ducts. [8] [9] [10] [11] b-cell neogenesis from other cell types within the pancreas, including acinar 12 and centroacinar 13 cells has also been reported.
Recently, we demonstrated robust b-cell neogenesis by transdifferentiation from preexisting a-cells in a model of T1D where severe b-cell deficiency was induced by high-dose alloxan. 14, 15 In this model, b-cell neogenesis from a-cells was stimulated by pancreatic duct ligation (PDL). 9, 15 Surgical reversal of PDL led to the recovery of b-cell mass and function by a combination of b-cell replication and b-cell neogenesis, demonstrating that b-cell regeneration by a-to b-cell neogenesis could be a robust approach to diabetes therapy, 16 but PDL, which involves major surgery, is not a practical approach to therapy. Importantly, the relevance of a-to b-cell transdifferentiation to human biology remained unclear, as previous studies were performed in rodents.
Here, we report the occurrence of efficient islet cell transdifferentiation using an entirely pharmacologically based approach where the peptide caerulein, 17, 18 substituting for PDL, stimulated b-cell transdifferentiation from a-cells in mice rendered severely b-cell deficient by alloxan. Following caerulein plus alloxan, many of the neogenic b-cells went on to form d-cells. In murine and human T1D, a similar process appeared to occur, where a-cells transdifferentiated into b-cells, which went on to form d-cells. This led to a marked d-cell excess in both murine and human T1D.
The finding of endocrine cell transdifferentiation in T1D supports a new paradigm where b-cells, in addition to undergoing destruction by inflammatory mediators, undergo a dynamic process of neogenesis from a-cells and transdifferentiation to d-cells. Controlling the neogenic process could lead to a new approach to diabetes therapy.
Results
Caerulein plus alloxan induced a-cells transdifferentiation into b-cells. As expected, 17, 19 Figures 1A-D) . Caerulin injection induced marked infiltration with CD3-positive lymphocytes, in contrast with alloxan injection that did not induce lymphocytic infiltration ( Supplementary  Figures 1E-H) . Caerulein had no effect on islet morphology or hormone expression (Supplementary Figures 1A-E) . Alloxan induced b-cell ablation, which we found previously to be required for endocrine cell transdifferentiation 9 ( Supplementary Figures 1G and H) .
In our previous study of a-to b-cell transdifferentiation, employing PDL plus alloxan to induce transdifferentiation, 9 the evidence for transdifferentiation as a cause of the increased b-cell mass was the finding of a high frequency of intermediates with glucagon-insulin coexpression, as well as the presence of little b-cell replication or neogenesis within ducts. 9 The high mortality following PDL plus alloxan hampered the genetic lineage tracing, which is considered to be the gold standard for determining lineage relationships. However, the alloxan plus caerulein model had lower mortality, allowing us to perform such studies.
For genetic lineage tracing of a-cells, we used mice expressing membrane-localized enhanced green fluorescent protein (eGFP; membrane-localized enhanced green fluorescent protein (mG)) on their a-cells while expressing membrane-localized Tomato (mT) on all other cells (GlumT/mG; Figure 1a ). Pancreases from Glu-mT/mG mice treated with alloxan alone or alloxan plus caerulein were analyzed 20 and 38 days post alloxan injection. In mice treated with alloxan alone, the few remaining b-cells expressed mT. Following alloxan plus caerulein, insulinpositive cells expressing mG, indicating an origin from recombined a-cells, were easily detected (Figures 1b-e Mice were killed at days 13, 20, 27 and 38 following alloxan plus caerulein or alloxan alone. At day 13, islets in both groups consisted primarily of a-cells and d-cells (Figures 2b and f , respectively-compare with normal islet in Figure 2a) . However, at day 13, there were consistently more b-cells in islets of the alloxan plus caerulein group (7.8% of total endocrine cells) compared with the alloxan alone group (1.3% of total endocrine cells; Figure 2f (Figures 2g-i, quantified in 2k) . The number of a-cells did not change significantly (Figure 2l ). This was expected, given our previous finding that a-cells replicate following PDL plus alloxan. 14 The initial rise in b-cell number followed by a decline (Figure 2j ), occurring concomitantly with a late rise in the number of d-cells (Figure 2k ), was consistent with the genetic lineage tracing experiment (Figure 1i ). Thus, both the lineage tracing and time course experiments support a model where As predicted by the a-to b-to d-cell model, glucagon-insulin coexpression was high at day 13, the earliest time-point studied, declined at day 27 and persisted until day 38 ( Figure 2m ). Insulin-somatostatin coexpressing cells rose later, peaking at day 27 ( Figure 2n ). Glucagon-somatostatin coexpression was never found at any time-point.
The sequential model predicts that transcription factors expressed in b-cells should be found in cells with glucagon-insulin and insulin-somatostatin coexpression. (m) Quantification of insulin-glucagon copositive area over time, demonstrating an increase of cells coexpressing insulin and glucagon following alloxan plus caerulein until day 38, when such cells were no longer present. There was no significant change in insulin-glucagon copositive cells following alloxan alone, never rising above the background. (n) Quantification of insulin-somatostatin copositive area over time, demonstrating an increase of cells coexpressing insulin and somatostatin following alloxan plus caerulein, peaking at day 27 and disappearing by day 38. There was no significant change in insulin-somatostatin copositive cells following alloxan alone, never rising above the background. Error bars are S.E.M. *Po0.05, **Po0.005, ***Po0.0005. Scale bar ¼ 75 mm
Thus, we examined the expression of the transcription factors pancreas-duodenum homeobox 1 (PDX1) and NK homeobox 6.1 (NKX6.1). Both of the transcription factors are expressed in all b-cells, with NKX6.1 being highly b-cell specific, 20, 21 while PDX1 is also expressed in a low percentage of d-cells.
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Neither is detected in a-cells. Following alloxan plus caerulein, there was a large increase in islet cells coexpressing PDX1 and glucagon, reaching a peak at day 13 when almost 25% of glucagon-positive cells also expressed PDX1 (Figure 3a In an independent experiment, mice were administered BrdU continuously following alloxan plus caerulein to mark cells that had replicated. Both BrdU-positive and negative cells that coexpressed insulin and somatostatin coexpression were found at day 20 (Supplementary Figure 6) . This is consistent with our previous study of islet cell transdifferentiation 9 and indicates that transdifferentiation occurred independently of replication.
In the time course experiment, six mice were maintained for at least 38 days following alloxan plus caerulein, from which two exhibited reduced blood glucose over time, whereas the others remained diabetic (Supplementary Figure 7A) . The mice with lower blood glucose were killed at days 38 and 62. In contrast to mice treated with alloxan alone, where a-cells were the predominant islet cell type at day 38 ( Supplementary  Figure 7B) , and the alloxan plus caerulein mice that remained diabetic at day 38 and where d-cells predominated (Supplementary Figure 7C) , the alloxan plus caerulein mice that became normoglycemic had many b-cells in their islets (Supplementary Figure 7D) . The islets had an intermixing of a-, b-and d-cells (Supplementary Figures 7D-H) .
Induction of islet cell transdifferentiation by alloxan plus caerulein was islet autonomous. Previously, we and others 9, 24 found that profound b-cell ablation was required to stimulate endocrine cell transdifferentiation. Moderate b-cell ablation (up to 80%) led to b-cell replication rather than transdifferentiation. 25 This suggested that a-cells sensed the number of b-cells and only when that fell below a certain threshold did transdifferentiation occur. The sensing mechanism could be a local phenomenon where a-cells sensed the proximate b-cell number, while sensing of the total b-cell mass was also a possibility.
Because the extent of b-cell ablation following alloxan injection varied between islets, we were able to measure the extent of transdifferentiation in islets that differed in the number of preexisting b-cells that survived alloxan. Using genetic lineage marking to distinguish between preexisting b-cells and neogenic b-cells, we counted the number of preexisting (mT expressing) and neogenic (mG expressing) b-cells in each islet. In islets with efficient b-cell ablation, there were many neogenic b-cells (Figures 4a-c) , whereas in islets with many b-cells that survived alloxan, there was little to no transdifferentiation, that is, the b-cells expressed mT on their membranes (Figures 4d-f ). There was a threshold effect, with the vast majority of transdifferentiated b-cells being found in islets with 10 or fewer preexisting b-cells that survived alloxan treatment (Figure 4g , P ¼ 0.0016). Only two mG-positive b-cells were found in islets with greater than ten preexisting b-cells. The threshold effect is consistent with a locally acting sensing mechanism where each islet behaves autonomously with respect to b-cell neogenesis from a-cells.
Endocrine cell transdifferentiation in the NOD mouse model of T1D. A logical next step was to examine T1D, the prototypical disease that combines inflammation with b-cell deficiency, for evidence of islet cell transdifferentiation. As genetic lineage tracing is not available in NOD mice, hormone colocalization, which we and others have shown to indicate islet cell transdifferentiation, 9,26,27 was used as a marker. As in the alloxan plus caerulein model, there was an increase in d-cells in the islets of NOD mice as they progressed from prediabetic to diabetic (Figure 5a , quantified in b and Supplementary Text).
Endocrine cell transdifferentiation in human T1D. To study transdifferentiation in human T1D (Supplementary  Table 1 ), we first asked whether there was a d-cell excess. As expected, islets were composed primarily of a-cells early in the course of disease (compare normal human pancreas in Figure 6a and Supplementary Figure 10 with early stage T1D pancreases in Figure 6b and Supplementary Figure 11) . As the number of years of diabetes increased, so did the frequency of d-cells (compare Figure 6b and Supplementary  Figure 11 with Figure 6c and Supplementary Figure 12) . The d-to a-cell ratio demonstrated a statistically significant increase as a direct function of the number of years of diabetes, which did not occur in non-diabetic or type II diabetic patients (Figures 6e and f) . In fact, the d-/a-cell ratio decreased in type II diabetes with duration of diabetes (Figure 6d and Supplementary Figure 13 , quantified in Figure 6f ), most likely due to the a-cell hyperplasia that occurs. 28 For direct evidence of transdifferentiation, we examined for intermediates in the process, finding cells with glucagoninsulin or insulin-somatostatin coexpression in some patients (Figures 6k-x , quantified in y and z, Supplementary Figures  11 and 14) , but not in all (Figure 6c, Supplementary  Figure 12 ). Cells coexpressing islet hormones were not found in non-diabetic controls (Figures 6g-j , quantified in y and z, Supplementary Figures 10 and 14) or patients with type II diabetes (Figure 6d, Supplementary Figure 13) . No glucagonsomatostatin coexpressing cells were found in any patient.
As in the mouse, we found islet cells coexpressing insulin, somatostatin and NKX6.1 in T1D but not normal pancreases (Supplementary Figure 15 , compare the non-diabetic patient in A-D where NKX6.1 was restricted to b-cells, with the T1D patient in E-G where there were cells that coexpressed insulin, somatostatin and NKX6.1).
Although the fact that some patients with T1D exhibited glucagon-insulin coexpression indicated that a-cells were Figure 3B) . Further examination of the cells coexpressing NKX6.1 and somatostatin revealed that in cells expressing somatostatin and NKX6.1 but not insulin, the NKX6.1 was invariably cytoplasmic (area outlined in red in Supplementary Figure 5E ). 39 In cells that coexpressed NKX6.1, somatostatin and insulin, NKX6.1 was usually nuclear (Supplementary Figures 5C-F ), but in rare cells was cytoplasmic. No cells coexpressing insulin and somatostatin but not NKX6.1 were found. Cytoplasmic expression of NKX6.1 has been described, with the suggestion that it is controlled by the redox state of the cell and that its localization may be important in Type II diabetes. 39 PDX1 also exhibited a transient increase in expression in cells expressing somatostatin, peaking at day 20 (quantified in f), which did not occur following alloxan alone (Supplementary Figure 3) In alloxan-injected mice, expression of PDX1 in d-cells remained constant over time at 9.5% (Supplementary Figure 3B , quantified in Figure 3f ), but rose to more than 40% at day 20 in alloxan plus caerulein treated mice (Figure 3c , quantified in f). Scale bar ¼ 75 mm Figure 14D and E and J-M). This is most consistent with direct transdifferentiation from b-to d-cells, but examination of additional patients will be required to determine how general this phenomenon is.
Discussion
Here, we demonstrate the existence of a novel pathway of islet cell neogenesis where a-cells transdifferentiate first to b-cells, with a subset going on to transdifferentiate into d-cells. Transdifferentiation was induced by a single peptide, caerulein, which was sufficient in the context of severe b-cell deficiency to promote a-to b-to d-cell transdifferentiation. A study of b-cell regeneration following profound b-cell ablation also found evidence of a-to b-cell transdifferentiation, but the efficiency of conversion was low. 24 Ectopic expression of the transcription factor Pax4 under the control of the glucagon promoter led to conversion of duct cells into b-cells, further validating the ability of cells expressing glucagon to convert into b-cells. 26, 29 However, an important difference is that we have not observed evidence of induction of transdifferentiating cells in the ducts, either here or in our previous study using PDL plus alloxan. Our data strongly indicate that hormone colocalization reflects transdifferentiation, as we never observed colocalization in normal mice. It was extremely rare even in the condition of pure b-cell ablation, studied previously by others. 24 We never observed glucagon-somatostatin coexpressing cells, which might have occurred if the hormone colocalization was an artifact of immunostaining. Similar to us, other groups have found hormone colocalization only in settings where transdifferentiation occurred as demonstrated by genetic lineage tracing. 26, 27 Consistent with our previous study of transdifferentiation following PDL plus alloxan, 9 we never observed hormone colocalization in ducts, nor did we ever observe mG-positive cells in ducts.
b-cell dedifferentiation has been reported as occurring in response to deletion of FoxO1 and in type II diabetes.
30,31 The finding of a high level of glucagon-insulin colocalization in the setting of profound b-cell ablation argues against b-cell dedifferentiation occurring following alloxan plus caerulein. First, there were simply not sufficient residual b-cells following alloxan to account for the large number of cells coexpressing glucagon and insulin. Also, dedifferentiation resulted in the loss of b-cell identity, that is, b-cell markers such as insulin, PDX1 and NKX6.1, before redifferentiation along a different lineage. 30 The glucagon-insulin and insulinsomatostatin coexpression, as well as somatostatin and NKX6.1, is not consistent with that phenomenon 30 and argues for transdifferentiation as opposed to dedifferentiation and redifferentiation as the mechanism responsible for a-to b-to d-cell conversion.
The d-cell excess in murine 32 and human T1D, with precisely the same intermediates as found in the alloxan plus caerulein model, demonstrates the relevance of endocrine cell transdifferentiation to autoimmune diabetes. However, endocrine cell transdifferentiation following alloxan plus caerulein occurred only in islets where there were few b-cells, whereas in T1D, transdifferentiation occurred in islets with a substantial number of residual b-cells, most likely reflecting a difference in the stimulus for transdifferentiation in autoimmunity versus that induced by caerulein. The simplest model that is consistent with the data presented here, postulating the existence of two factors, one positive and one repressive, is shown in Supplementary Figure 16 .
In some human patients with T1D, islets were found with numerous b-cells, all of which coexpressed somatostatin, and with no evidence of a-to b-cell transdifferentiation, suggesting that direct b-to d-cell transdifferentiation was taking place without an a-cell origin. Such islets were fairly normal in morphology, with a large number of b-cells located more centrally, all of which coexpressed somatostatin but with no glucagon-insulin colocalization. Analysis of additional patient samples, which are rare, will be of value in determining the degree to which this occurs in the general population of type I diabetics. Of importance, islet cell transdifferentiation was found to occur regardless of age or duration of diabetes, suggesting that stimulating this process might be a viable approach to therapy in individuals with longstanding T1D. This is in contrast to b-cell replication, the other major approach to b-cell regeneration, which declines markedly with age, [33] [34] [35] but is consistent with our previous finding in the PDL plus alloxan model, where a-to b-cell transdifferentiation occurred in old mice. 9 The dramatic d-cell excess in murine and human T1D, combined with the observation that b-cells appear to be able to transdifferentiate directly into d-cells, indicates that the conventional paradigm of T1D where b-cells are destroyed by autoimmunity is incomplete. Rather, in addition to autoimmune destruction of b-cells, the view of islet cell kinetics in T1D should be modified to take into account the endocrine cell transdifferentiation from a-to b-cells and b-to d-cells. If the process of bto d-cell transdifferentiation is reversible, that may provide another route to b-cell regeneration in T1D. Regardless, the finding of efficient a-to b-cell transdifferentiation in T1D, as well as the finding that a single peptide is sufficient to drive transdifferentiation, raises the prospect that b-cell regeneration by the mobilization of a-and possibly d-cells functioning as facultative b-cell stem cells may be feasible.
Materials and Methods
Mice. Glu-mT/mG mice for a-cell lineage tracing were a generous gift from Dr. Mark Huising (The Salk Institute for Biological Studies, La Jolla, California (USA)). Gt(ROSA)26Sor tm4(ACTB-tdTomato,-EGFP)Luo /J (The Jackson laboratory (Bar Harbor, Maine)-stock # 007576) 36 were crossed with Glucagon-Cre mice, expressing cre recombinase under the control of the glucagon promoter. 37 This transgene has been well characterized in multiple studies, exhibiting very low to undetectable background recombination. 37, 38 F1 mice were genotyped and mice positive for both markers were selected for the study. The F1 mice (Glu-mT/mG) have the mT cassette deleted in cre-expressing cells, while a membrane-targeted eGFP (mG) cassette is activated. Thus, a-cells and cells derived from a-cells that underwent cre-mediated recombination have a green fluorescent membrane, whereas preexisting cells not arising from recombined a-cells have a red fluorescent membrane. To calculate the recombination efficiency in a-cells, 444 cells from 12 mice were counted. Alloxan plus caerulein. Mice were injected intravenously with 110 mg/kg alloxan (Sigma-Aldrich, St. Louis, MO, USA) in PBS (phosphate-buffered saline) at day 1. Mice with a blood glucose level greater than 500 mg/dl (OneTouch Ultra Mini, Johnson & Johnson, Milpitas, CA, USA) were randomized into two groups. One group was injected with caerulein (Sigma-Aldrich; six IP injections on days 1, 3 and 5). Lineage tracing studies were done with a caerulein dose of 7 mg/kg and the time course study with C57BL/6 mice used a dose of 10 mg/kg in PBS. Mice (alloxan alone and alloxan plus caerulein) were killed on days:
Day 13-Three C57BL/6 alloxan plus caerulein mice, three C57BL/6 alloxan alone mice.
Day 20-Three lineage tracing alloxan plus caerulein mice, three lineage tracing alloxan alone mice, seven C57BL/6 alloxan plus caerulein mice, seven C57BL/6 alloxan alone mice. Of the seven C57BL/6 alloxan plus caerulein mice and seven alloxan alone mice, one group from each (n ¼ 3) had BrdU (1 mg/ml, Sigma-Aldrich) added to the drinking water, whereas the second (n ¼ 4) had no BrdU added.
Day 27-Three C57BL/6 alloxan plus caerulein mice, three C57BL/6 alloxan alone mice.
Day 38-Three lineage tracing alloxan plus caerulein mice, three lineage tracing alloxan alone mice, four C57BL/6 alloxan plus caerulein and four C57BL/6 alloxan alone.
NOD mouse experiments. Twenty 8.5 month-old non-diabetic NOD mice (blood glucose levels 80-200 mg/dl) and five diabetic NOD mice (age 6-15 months-old) were killed. Of the 20 non-diabetic NOD mice, six had an islet morphology typical of early stages of diabetes-that is, some islets with insulitis, disorganized islet morphology and transdifferentiating cells. Fourteen non-diabetic mice had no evidence of islet autoimmunity and were not analyzed further. Red diamonds mark the age of type I diabetics and red squares mark the duration of T1D, connected by a black line for each patient. Blue circles mark the age of non-diabetic patients. Pearson's coefficient for T1D was 0.61 and for non-diabetic patients was À 0.74. (f) Quantification of the somatostatin-positive area normalized to the glucagon-positive area in patients with T1D greater than 20 years, compared with non-diabetic and type II diabetic patients, demonstrating a statistically significant increase in the number of d-cells in the type I diabetic patients with years of disease. (g-r) Islet hormone coexpression in a non-diabetic patient (NPOD Donor #6178) (g-j), nPOD Donors #6052 and #6038, with T1D for 1 year (k-n) and 20 years (o-r), respectively. Coexpression was analyzed by the ImageJ colocalization analysis highlighter algorithm that analyzes two channels (red and green) and marks colocalized areas in white. Insulin and glucagon (red and green in g, k and o), insulin and somatostatin (red and green in h, l and p), and somatostatin and glucagon (red and green in i, m and q). Note that all of the colors from the Image J analysis are pseudocolors. True colors from the same islets are shown in j, n and r. Examples of insulin and glucagon coexpression are shown in high power in s and t (double positive areas are indicated by a dashed white line), and of insulin and somatostatin coexpression in u-x (double positive areas are indicated by a dashed yellow line). Quantification of insulin and glucagon coexpression is presented in y and for insulin and somatostatin in z in nPOD Donors #6052, #6196, #6081 and #6038 (Supplementary Table 1 ). These patients were selected because their pancreas had islets with a significant number of b-cells and only islets with greater than 20 b-cells were subjected to quantitative analysis. No colocalization between glucagon and somatostatin was found and so it could not be quantified. Coexpression was indistinguishable from background in the normal patient, but there was extensive insulin-glucagon coexpression in nPOD patients 6052, 6196 and 6081. Donors 6081 and 6038 had a high level of insulin and somatostatin coexpression. Quantification was performed on confocal images (Supplementary Figure 14) . Error bars are S.E.M. of individual islets. Islets from five non-diabetic patients were pooled. Scale bar for i-t ¼ 75 mm 
